Skip to main content
. Author manuscript; available in PMC: 2009 Jun 8.
Published in final edited form as: FEBS Lett. 2008 Apr 16;582(12):1637–1642. doi: 10.1016/j.febslet.2008.04.009

Figure 3.

Figure 3

RNAi knockdown of ROCK 1 and PRK-2 abolishes the inhibitory effect of Y-27632 on polyglutamine aggregation. Control siRNA or siRNAs targeting ROCK 1 or PRK-2 were transfected into HEK293 cells, alone or with ARN127(Q65)CFP/YFP or Htt exon 1(Q72)CFP/YFP. Aggregation was measured by FRET. (A) Western blot confirmed the successful knockdowns of ROCK 1 and PRK-2. (B) RNAi knockdown of ROCK 1 and PRK-2 reduces polyglutamine aggregation. Effects of ROCK 1 or PRK-2 knockdown were expressed as relative FRET/donor ratios vs. cells transfected with the control siRNA. (C) RNAi knockdown of ROCK 1 and PRK-2 abolishes the inhibitory effect of Y-27632 on polyglutamine aggregation. Effects of 50μM Y-27632 were calculated as relative FRET/donor ratios vs. untreated cells in the presence of control, ROCK 1, or PRK-2 siRNAs. ROCK1 or PRK-2 knockdowns each partially reduced the inhibitory effect of Y-27632, and their simultaneous knockdown abolished it, slightly increasing aggregation in response to treatment. Error bars represent the S.E.M. Statistical significance was calculated using the unpaired t-test (* p<0.05, ** p<0.01, *** p<0.005).